| 2024 | Genomic and transcriptomic profiles associated with response to eribulin and nivolumab combination in HER-2-negative metastatic breast cancer
| CANCER IMMUNOLOGY IMMUNOTHERAPY |
| 2024 | Overcoming BRAF and CDK4/6 inhibitor resistance by inhibiting MAP3K3-dependent protection against YAP lysosomal degradation
| EXPERIMENTAL AND MOLECULAR MEDICINE |
| 2024 | Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study
| CLINICAL CANCER RESEARCH |
| 2023 | Clinical activity of nivolumab in combination with eribulin in HER2-negative metastatic breast cancer: A phase IB/II study (KCSG BR18-16)
| EUROPEAN JOURNAL OF CANCER |
| 2023 | Pembrolizumab Plus Chemotherapy Followed by Pembrolizumab in Patients With Early Triple-Negative Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial | JAMA NETWORK OPEN |
| 2023 | Efficacy of Limited Dose Modifications for Palbociclib-Related Grade 3 Neutropenia in Hormone Receptor-Positive Metastatic Breast Cancer
| CANCER RESEARCH AND TREATMENT |
| 2023 | Copy number aberrations in circulating tumor DNA enables prognosis prediction and molecular characterization of breast cancer | JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE |
| 2023 | Genomic analysis of plasma circulating tumor DNA in patients with heavily pretreated HER2 + metastatic breast cancer
| SCIENTIFIC REPORTS |
| 2023 | Integrative modeling of tumor genomes and epigenomes for enhanced cancer diagnosis by cell-free DNA
| NATURE COMMUNICATIONS |
| 2023 | Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer refractory to gemcitabine and cisplatin: a multi-institutional phase 2 trial of the Korean Cancer Study Group (KCSG-HB19-14) | LANCET GASTROENTEROLOGY & HEPATOLOGY |
| 2023 | On-treatment derived neutrophil-to-lymphocyte ratio and survival with palbociclib and endocrine treatment: analysis of a multicenter retrospective cohort and the PALOMA-2/3 study with immune correlates
| BREAST CANCER RESEARCH |
| 2023 | Anaemia and pathologic complete response rate according to carboplatin dose in HER2+ breast cancer treated with neoadjuvant TCHP
| CANCER MEDICINE |
| 2022 | Data collection framework for electronic medical record-based real-world data to evaluate the effectiveness and safety of cancer drugs: a nationwide real-world study of the Korean Cancer Study Group | THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY |
| 2022 | Phase II study to investigate the efficacy of trastuzumab biosimilar (Herzuma®) plus treatment of physician's choice (TPC) in patients with heavily pretreated HER-2+ metastatic breast cancer (KCSG BR 18-14/KM10B) | BREAST |
| 2022 | Response Rate and Safety of a Neoadjuvant Pertuzumab, Atezolizumab, Docetaxel, and Trastuzumab Regimen for Patients With ERBB2-Positive Stage II/III Breast Cancer: The Neo-PATH Phase 2 Nonrandomized Clinical Trial
| JAMA ONCOLOGY |
| 2022 | PS2-3 Neoadjuvant pembrolizumab/placebo + chemo, followed by adjuvant pembrolizumab/placebo in early TNBC: Asian subgroup | ANNALS OF ONCOLOGY |
| 2022 | PS2-1 Trastuzumab deruxtecan vs T-DM1 in HER2+ mBC in Asian subgroup: Results of the randomized phase 3 study DESTINY-Breast03 | ANNALS OF ONCOLOGY |
| 2022 | Molecular Characterization of BRCA1 c.5339T>C Missense Mutation in DNA Damage Response of Triple-Negative Breast Cancer
| CANCERS |
| 2022 | Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer | NEW ENGLAND JOURNAL OF MEDICINE |
| 2022 | A multi-institutional, single-arm, phase II trial of neoadjuvant modified-FOLFIRINOX for resectable pancreatic ductal adenocarcinoma | JOURNAL OF CLINICAL ONCOLOGY |
| 2022 | SKI-G-801, an AXL kinase inhibitor, blocks metastasis through inducing anti-tumor immune responses and potentiates anti-PD-1 therapy in mouse cancer models
| CLINICAL & TRANSLATIONAL IMMUNOLOGY |
| 2022 | Combined tumor epithelial and stromal histopathology with keratin 81 expression predicts prognosis for pancreatic ductal adenocarcinoma | JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES |
| 2022 | Protective effect of bisphosphonate on the cortical bone at key locations of the femur in aromatase inhibitor-associated bone loss: A three-dimensional cortical bone mapping study
| JOURNAL OF BONE ONCOLOGY |
| 2021 | Molecular Characterization of Biliary Tract Cancer Predicts Chemotherapy and Programmed Death 1/Programmed Death-Ligand 1 Blockade Responses | HEPATOLOGY |
| 2021 | Real-world efficacy and safety of nab-paclitaxel plus gemcitabine-cisplatin in patients with advanced biliary tract cancers: a multicenter retrospective analysis
| THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY |
| 2021 | Distinct Characteristics and Clinical Outcomes to Predict the Emergence of MET Amplification in Patients with Non-Small Cell Lung Cancer Who Developed Resistance after Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
| CANCERS |
| 2021 | Real-World Clinical Outcomes of Biosimilar Trastuzumab (CT-P6) in HER2-Positive Early-Stage and Metastatic Breast Cancer
| FRONTIERS IN ONCOLOGY |
| 2021 | Genomic landscape of extraordinary responses in metastatic breast cancer
| COMMUNICATIONS BIOLOGY |
| 2020 | Palbociclib use with grade 3 neutropenia in hormone receptor-positive metastatic breast cancer | BREAST CANCER RESEARCH AND TREATMENT |
| 2020 | Molecular subtypes of oropharyngeal cancer show distinct immune microenvironment related with immune checkpoint blockade response
| BRITISH JOURNAL OF CANCER |
| 2020 | Intermediate HER2 Expression Is Associated With Poor Prognosis in Estrogen Receptor-Positive Breast Cancer Patients Aged 55 Years and Older | BREAST CANCER RESEARCH AND TREATMENT |
| 2019 | MK5 Regulates YAP Stability and Is a Molecular Target in YAP-Driven Cancers | CANCER RESEARCH |
| 2019 | Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK-rearranged lung cancer
| EMBO MOLECULAR MEDICINE |
| 2019 | Mesothelin Expression Is a Predictive Factor for Peritoneal Recurrence in Curatively Resected Stage III Gastric Cancer | ONCOLOGIST |
| 2019 | Immunohistochemistry Biomarkers Predict Survival in Stage II/III Gastric Cancer Patients: From a Prospective Clinical Trial
| Cancer Research and Treatment |
| 2018 | Can We Prevent Resistance to Osimertinib? Combination or Sequential | JOURNAL OF THORACIC ONCOLOGY |
| 2017 | Different subtypes of epithelioid sarcoma and their clinical implication: long-term multi-institutional experience with a rare sarcoma | APMIS |
| 2015 | Anaplastic lymphoma kinase gene copy number gain in inflammatory breast cancer (IBC): prevalence, clinicopathologic features and prognostic implication
| PLOS ONE |
| 2014 | Impact of cigarette smoking on response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in lung adenocarcinoma with activating EGFR mutations | LUNG CANCER |
| 2014 | Ifosfamide-induced Fanconi syndrome with diabetes insipidus
| KOREAN JOURNAL OF INTERNAL MEDICINE |
| 2014 | Clinical and prognostic implications of ALK and ROS1 rearrangements in never-smokers with surgically resected lung adenocarcinoma | LUNG CANCER |
| 2013 | Changing treatment patterns in elderly patients with resectable colon cancer | ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY |
| 2013 | FOXP3 Expression Is Related to High Ki-67 Index and Poor Prognosis in Lymph Node-Positive Breast Cancer Patients | ONCOLOGY |
| 2012 | 신장 재이식 환자의 다발성 내장 침범 카포시육종에서 Sirolimus 치료를 통한 부분 관해 및 이식신 보존 1예
| Journal of the Korean Society for Transplantation |
http://orcid.org/0000-0002-1595-6342
